(Difference between pages)

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

Content deleted Content addedVisualWikitext

Revision as of 13:23, 5 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{chembox}} taken from revid 456944841 of page Pixantrone for the Chem/Drugbox validation project (updated: 'CASNo').		Latest revision as of 19:34, 17 July 2024 edit Citation bot (talk | contribs)Bots5,420,409 edits Altered template type. | Use this bot. Report bugs. | Suggested by Abductive | Category:Withdrawn drugs | #UCB_Category 115/223
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{ambox | text = This page contains a copy of the infobox ({{tl|chembox}}) taken from revid of page ] with values updated to verified values.}}
			{{Use dmy dates|date=July 2024}}
	{{chembox
			{{cs1 config |name-list-style=vanc |display-authors=6}}
			{{Chembox
	| Verifiedfields = changed		| Verifiedfields = changed
			| verifiedrevid = 464208373
	| UNII_Ref = {{fdacite|changed|FDA}}
			| ImageFile=Pixantrone.svg
	| UNII = F5SXN2KNMR
			| ImageSize=
	| verifiedrevid = 413276732
			| PIN=6,9-Bisbenzoisoquinoline-5,10-dione
	|ImageFile=Pixantrone.svg
			| OtherNames=
	|ImageSize=
			|Section1={{Chembox Identifiers
	|IUPACName=6,9-bisbenzoisoquinoline-5,10-dione
			| CASNo_Ref = {{cascite|correct|CAS}}
	|OtherNames=
			| CASNo=144510-96-3
	|Section1= {{Chembox Identifiers
			| ChEBI = 135945
	| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
			| IUPHAR_ligand = 7544
			| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
	| ChemSpiderID = 118174		| ChemSpiderID = 118174
			| DrugBank = DB06193
	| KEGG_Ref = {{keggcite|correct|kegg}}		| KEGG_Ref = {{keggcite|correct|kegg}}
	| KEGG = D05522		| KEGG = D05522
	| InChI = 1/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
	| InChIKey = PEZPMAYDXJQYRV-UHFFFAOYAV
	| ChEMBL_Ref = {{ebicite|correct|EBI}}		| ChEMBL_Ref = {{ebicite|correct|EBI}}
	| ChEMBL = 167731		| ChEMBL = 167731
			| PubChem=134019
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = F5SXN2KNMR
			| InChI = 1/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
			| InChIKey = PEZPMAYDXJQYRV-UHFFFAOYAV
	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}		| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChI = 1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2		| StdInChI = 1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
	| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}		| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChIKey = PEZPMAYDXJQYRV-UHFFFAOYSA-N		| StdInChIKey = PEZPMAYDXJQYRV-UHFFFAOYSA-N
	| CASNo_Ref = {{cascite|correct|??}}
	| CASNo = <!-- blanked - oldvalue: 144510-96-3 -->
	| PubChem=134019
	| SMILES = O=C2c3c(C(=O)c1c(ccc(NCCN)c12)NCCN)cncc3		| SMILES = O=C2c3c(C(=O)c1c(ccc(NCCN)c12)NCCN)cncc3
	| ATCCode_prefix = L01
	| ATCCode_suffix = DB11
	}}		}}
	|Section2= {{Chembox Properties		|Section2={{Chembox Properties
	| Formula=C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>		| Formula=C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>
	| MolarMass=325.365 g/mol		| MolarMass=325.365 g/mol
	| Appearance=Blue solid		| Appearance=Blue solid
	| Density=		| Density=
	| MeltingPt=		| MeltingPt=
	| BoilingPt=		| BoilingPt=
	| Solubility=		| Solubility=
	}}		}}
	|Section3= {{Chembox Hazards		|Section7={{Chembox Hazards
	| MainHazards=		| MainHazards=
	| FlashPt=		| FlashPt=
			| AutoignitionPt =
	| Autoignition=
	}}		}}
	| Section4 = {{Chembox Pharmacology		| Section6 = {{Chembox Pharmacology
			| Pharmacology_ref =
			| ATCCode_prefix = L01
			| ATCCode_suffix = DB11
			| ATC_Supplemental =
			| ATCvet =
			| Licence_EU =
			| INN =
			| INN_EMA =
			| Licence_US =
			| Legal_status =
			| Legal_AU =
			| Legal_AU_comment =
			| Legal_CA =
			| Legal_CA_comment =
			| Legal_NZ =
			| Legal_NZ_comment =
			| Legal_UK = POM
			| Legal_UK_comment = /{{nbsp}}Discontinued<ref>{{cite web | title=Pixuvri 29 mg powder for concentrate for solution for infusion | website=(emc) | date=23 November 2021 | url=https://www.medicines.org.uk/emc/product/3662 | access-date=12 July 2024}}</ref>
			| Legal_US =
			| Legal_US_comment =
			| Legal_EU = Rx-only
			| Legal_EU_comment = /{{nbsp}}Expired<ref name="Pixuvri EPAR" />
			| Legal_UN =
			| Legal_UN_comment =
			| Pregnancy_category =
			| Pregnancy_AU =
			| Pregnancy_AU_comment =
			| Dependence_liability =
	| AdminRoutes = ]		| AdminRoutes = ]
	| Bioavail =		| Bioavail =
			| ProteinBound =
	| Metabolism =		| Metabolism =
			| Metabolites =
			| OnsetOfAction =
	| HalfLife = 9.5–17.5 hours		| HalfLife = 9.5–17.5 hours
			| DurationOfAction =
	| ProteinBound =
	| Excretion = Fecal (main route of excretion) and renal (4–9%)		| Excretion = Fecal (main route of excretion) and renal (4–9%)
			}}
	| Legal_status =
	| Legal_US =
	| Legal_UK =
	| Legal_AU =
	| Legal_CA =
	| PregCat =
	| PregCat_AU =
	| PregCat_US = }}
	}}		}}
			'''Pixantrone''' (]; trade name '''Pixuvri''')
			is an experimental ] (anti-cancer) drug, an ] of ] with fewer ] effects on ] tissue.<ref name="pmid17285358"/> It acts as a ] poison and ].<ref name="pmid7623772"/><ref name="pmid17483512">{{cite journal |vauthors=Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM |title=Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent |journal=Nucleic Acids Res. |volume=35 |issue=11 |pages=3581–9 |year=2007 |pmid=17483512 |pmc=1920253 |doi=10.1093/nar/gkm285 |url=}}</ref> The code name '''BBR 2778''' refers to '''pixantrone dimaleate''', the actual substance commonly used in clinical trials.<ref name="pmid8145234">{{cite journal |vauthors=Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP, Giuliani FC, Beggiolin G, Pezzoni G, Menta E, Manzotti C, Oliva A, Spinelli S, Tognella S |title=6,9-Bisbenzoisoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations |journal=J Med Chem |volume=37 |issue=6 |pages=828–37 |year=1994 |pmid=8145234 |doi=10.1021/jm00032a018 }}</ref>
			==History==
			]s are important ] agents. However, their use is associated with irreversible and cumulative ] damage. Investigators have attempted to design related drugs that maintain the biological activity, but do not possess the cardiotoxicity of the anthracyclines.<ref name ="uspatent"/> Pixantrone was developed to reduce heart damage related to treatment while retaining efficacy.<ref name="pmid17285358">{{cite journal |vauthors=Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F |title=Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone |journal=Invest New Drugs. |volume=25 |issue=3 |pages=187–95 |year=2007 |pmid=17285358 |doi=10.1007/s10637-007-9037-8|s2cid=20933712 }}</ref>
			Random screening at the US ] of a vast number of compounds provided by the ] led to the discovery of ] as having significant ] activity. Further investigation regarding the rational development of analogs of ametantrone led to the synthesis of ], which also exhibited marked anti-tumor activity<ref name ="uspatent"/> Mitoxantrone was considered as an analog of ] with less structural complexity but with a similar mode of action. In clinical studies, mitoxantrone was shown to be effective against numerous types of tumors with less toxic side effects than those resulting from doxorubicin therapy. However, mitoxantrone was not totally free of cardiotoxicity. A number of structurally modified analogs of mitoxantrone were synthesized and structure-activity relationship studies made.<ref name ="uspatent"/> BBR 2778 was originally synthesized by University of Vermont researchers Miles P. Hacker and Paul A. Krapcho<ref name ="uspatent">{{ cite patent | country = US | number = 5587382 | status = patent | title = 6,9-bisbenzo isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity | pubdate = | gdate = 24 December 1996 | fdate = 1995-06-06 | pridate = | inventor = Krapcho AP, Hacker MP, Cavalletti E, Giuliani FC | assign1 = Boehringer Mannheim Italia, SpA }}</ref> and initially characterized in vitro for tumor cell cytotoxicity and mechanism of action by studies at the Boehringer Mannheim Italia Research Center, ], and ], ].<ref name="pmid8145234"/> Other studies have been completed at ], ], the ], ], and the ].<ref name="pmid7623772">{{cite journal |vauthors=De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC, Zunino F |title=Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives |journal=Mol. Pharmacol. |volume=48 |issue=1 |pages=30–8 |year=1995 |pmid=7623772}}</ref><ref name="pmid8145234"/><ref name="pmid8394077">{{cite journal |vauthors=Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP |title=Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II |journal=Biochem. Pharmacol. |volume=46 |issue=2 |pages=265–71 |year=1993 |pmid=8394077 |doi=10.1016/0006-2952(93)90413-Q}}</ref> In the search for novel heteroanalogs of anthracenediones, it was selected as the most promising compound. Toxicological studies indicated that BBR 2778 was not cardiotoxic, and US patents are held by the University of Vermont. An additional US patent application was completed in June 1995 by Boehringer Mannheim, Italy.<ref name ="uspatent"/>
			Novuspharma, an Italian company, was established in 1998 following the merger of Boehringer Mannheim and ], and BBR 2778 was developed as Novuspharma's leading anti-cancer drug, pixantrone.<ref name="pmid12789604">{{cite journal |vauthors=Borchmann P, Reiser M | title = Pixantrone (Novuspharma) | journal = IDrugs | volume = 6 | issue = 5 | pages = 486–90 |date=May 2003 | pmid = 12789604 }}</ref> A patent application for the injectable preparation was filed in May 2003.<ref name ="eppatent">{{ cite patent | country = EP | number = 1503797 | status = patent | title = Injectable Pharmaceutical Compositions of an Anthracenedione Derivative with Anti-Tumoral Activity | pubdate = 27 November 2003 | gdate = 2008-09-29 | fdate = 2003-09-05 | pridate = 2002-05-16 | inventor = Bernareggi A, Livi V | assign1 = Cell Therapeutics Europe S.R.L. }}</ref>
			In 2003, ], a ] biotechnology company, acquired pixantrone through a merger with Novuspharma.<ref name="Pollack2003">{{cite news| url=https://www.nytimes.com/2003/06/17/business/company-news-cell-therapeutics-announces-plan-to-buy-novuspharma.html?sec=health | work=The New York Times | title=Company News; Cell Therapeutics Announces Plan To Buy Novuspharma | first=Andrew | last=Pollack | date=17 June 2003 | access-date=22 May 2010}}</ref>
			=== Clinical trials ===
			Pixantrone is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics.<ref name="urlantineoplastic antibiotic - definition of antineoplastic antibiotic.">{{cite web | url = http://medical-dictionary.thefreedictionary.com/antineoplastic+antibiotic | title = definition of antineoplastic antibiotic | author = Mosby's Medical Dictionary, 8th edition. © 2009, Elsevier. | publisher = Free Online Medical Dictionary, Thesaurus and Encyclopedia | access-date = 31 January 2012 }}</ref> ] ]s of pixantrone have been completed.<ref name="NCT00088530">{{cite web | url = http://clinicaltrials.gov/ct/show/NCT00088530 | title = NCT00088530 | work = BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | publisher = ClinicalTrials.gov | access-date = 31 January 2012 }}</ref><ref name="urlFludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - Full Text View - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct/show/NCT00551239 | title = NCT00551239 | date = 31 January 2012 | work = Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | publisher = ClinicalTrials.gov | access-date = 31 January 2012 }}</ref> Pixantrone is being studied as an ] for different kinds of ], including solid tumors and ] such as ]s.
			Animal studies demonstrated that pixantrone does not worsen pre-existing heart muscle damage, suggesting that pixantrone may be useful in patients pretreated with anthracyclines. While only minimal cardiac changes are observed in mice given repeated cycles of pixantrone, 2 cycles of traditional anthracyclines doxorubicin or mitoxantrone result in marked or severe heart muscle degeneration.<ref name="pmid17285358"/>
			Clinical trials substituting pixantrone for doxorubicin in standard first-line treatment of patients with aggressive non-Hodgkin's lymphoma, had a reduction in severe side effects when compared to patients treated with standard doxorubicin-based therapy. Despite pixantrone patients receiving more treatment cycles, a three-fold reduction in the incidence of severe heart damage was seen as well as clinically significant reductions in infections and thrombocytopenia, and a significant reduction in febrile neutropenia. These findings could have major implications for treating patients with breast cancer, lymphoma, and leukemia, where debilitating cardiac damage from doxorubicin might be prevented.<ref name="urlPixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy">{{cite press release | url = http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/07-11-2007/0004623260 | title = Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy | work = Press Release | access-date = 31 January 2012 }}</ref> Previous treatment options for multiply relapsed aggressive ] had disappointing response rates.<ref name="pmid17026830"/>
			The completed phase II RAPID trial compared the CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to the same regimen, but substituting Doxorubicin with Pixantrone. The objective was to show that Pixantrone was not inferior to Doxorubicin and less toxic to the heart.<ref name="NCT00268853">{{cite web | url = http://clinicaltrials.gov/ct2/show/NCT00268853 | title = NCT00268853 | work = A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | publisher = ClinicalTrials.gov | access-date = 31 January 2012 }}</ref>
			Pixantrone was shown to have potentially reduced cardiotoxicity and demonstrated promising clinical activity in these phase II studies in heavily pretreated ] patients.<ref name="pmid17026830">{{cite journal |vauthors=Engert A, Herbrecht R, Santoro A, Zinzani PL, Gorbatchevsky I | title = EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma | journal = Clin Lymphoma Myeloma | volume = 7 | issue = 2 | pages = 152–4 |date=September 2006 | pmid = 17026830 | doi = 10.3816/CLM.2006.n.055 }}</ref>
			The phase III EXTEND (PIX301) randomized clinical trial studied pixantrone to see how well it works compared to other chemotherapy drugs in treating participants with relapsed non-Hodgkin's lymphoma.<ref name="NCT00101049">{{cite web | url = http://clinicaltrials.gov/ct/show/NCT00101049 | title = NCT00101049 | work = BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | publisher = ClinicalTrials.gov | access-date = 31 January 2012 }}</ref> The complete response rate in pixantrone treated with pixantrone has been significantly higher than in those receiving other chemotherapeutic agents for treatment of relapsed/refractory aggressive ].<ref name="pmid17026830"/>
			==Administration==
			It can be administered through a peripheral vein rather than a central implanted catheter as required for other similar drugs.<ref name ="eppatent"/><ref name="pmid17026830"/>
			== Society and culture ==
			=== Legal status ===
			=== US Food and Drug Administration ===
			The US ] (FDA) granted fast track designation for pixantrone in people who had previously been treated two or more times for relapsed or refractory aggressive Non-Hodgkin's Lymphoma. Study sponsor Cell Therapeutics announced that pixantrone achieved the primary efficacy endpoint. The minutes of the Oncologic Drugs Advisory Committee meeting of 22 March 2010<ref name="urlwww.fda.gov">{{cite web | url = https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM207638.pdf | title = NDA 022-481 PIXUVRI (pixantrone dimaleate) injection |vauthors=Vesely N, Eckhardt SG | date = 22 March 2010 | work = Summary Minutes of the Oncologic Drugs Advisory Committee | publisher = United States Food and Drug Administration | access-date = 31 January 2012 }}</ref> show that this had not in fact been achieved with statistical significance and this combined with major safety concerns lead to the conclusion that the trial was not sufficient to support approval. In April 2010, the FDA asked for an additional trial.<ref>{{cite news | url = http://www.genengnews.com/gen-news-highlights/cell-therapeutics-formally-appeals-fda-s-nonapprovable-ruling-for-pixantrone/81244332/ | title = Cell Therapeutics Formally Appeals FDA's Nonapprovable Ruling for Pixantrone | date = 3 December 2010 | publisher = GEN News }}</ref>
			=== European Medicines Agency ===
			In May 2009, pixantrone became available in the European Union on a named-patient basis. A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying individuals. Under a named-patient program, investigational drugs can be administered to people who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual. In the European Union, under the named-patient program the drug is most often purchased through the national health system.<ref name="urlPixantrone Now Available in Europe on a Named-Patient Basis">{{cite web| url =http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=104&STORY=/www/story/05-05-2009/0005019037| title =Pixantrone Now Available in Europe on a Named-Patient Basis| archive-date =1 October 2009| access-date =31 January 2012| url-status =dead| archive-url =https://web.archive.org/web/20091001154001/http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=104}}</ref>
			In 2012, pixantrone received conditional marketing authorization in the European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas.<ref>{{cite journal | vauthors = Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F | title = The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use | journal = The Oncologist | volume = 18 | issue = 5 | pages = 625–33 | date = 2013 | pmid = 23615696 | pmc = 3662855 | doi = 10.1634/theoncologist.2013-0020 }}</ref><ref name="Pixuvri EPAR">{{cite web | title=Pixuvri EPAR | website=European Medicines Agency | date=31 May 2012 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri | access-date=12 July 2024}}</ref> The authorization expired in July 2024, after the holder decided not to renew.<ref name="Pixuvri EPAR" />
			==Research==
			Pixantrone is as potent as mitoxantrone in animal models of ].<ref name="pmid15261566">{{cite journal |vauthors=Gonsette RE, Dubois B | title = Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity | journal = J. Neurol. Sci. | volume = 223 | issue = 1 | pages = 81–6 |date=August 2004 | pmid = 15261566 | doi = 10.1016/j.jns.2004.04.024 | s2cid = 35170743 }}</ref> Pixantrone has a similar mechanism of action as mitoxantrone on the effector function of lymphomonocyte B and T cells in experimental allergic encephalomyelitis but with lower cardiotoxicity. Pixantrone inhibits antigen specific and mitogen induced lymphomononuclear cell proliferation, as well as IFN-gamma production.<ref name="pmid16120465">{{cite journal |vauthors=Mazzanti B, Biagioli T, Aldinucci A, Cavaletti G, Cavalletti E, Oggioni N, Frigo M, Rota S, Tagliabue E, Ballerini C, Massacesi L, Riccio P, Lolli F | title = Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis | journal = J. Neuroimmunol. | volume = 168 | issue = 1–2 | pages = 111–7 |date=November 2005 | pmid = 16120465 | doi = 10.1016/j.jneuroim.2005.07.010 | s2cid = 32913479 }}</ref> Clinical trials are currently ongoing in Europe.
			Pixantrone also reduces the severity of experimental autoimmune ] in Lewis rats,<ref name="pmid18250482">{{cite journal |vauthors=Ubiali F, Nava S, Nessi V, Longhi R, Pezzoni G, Capobianco R, Mantegazza R, Antozzi C, Baggi F | title = Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats | journal = J. Immunol. | volume = 180 | issue = 4 | pages = 2696–703 |date=February 2008 | pmid = 18250482 | doi = 10.4049/jimmunol.180.4.2696| doi-access = free }}</ref> and in vitro cell viability experiments indicated that Pixantrone significantly reduces amyloid beta (A beta(1-42)) neurotoxicity, a mechanism implicated in ].<ref name="pmid19306269">{{cite journal |vauthors=Colombo R, Carotti A, Catto M, Racchi M, Lanni C, Verga L, Caccialanza G, De Lorenzi E | title = CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity | journal = Electrophoresis | volume = 30 | issue = 8 | pages = 1418–29 |date=April 2009 | pmid = 19306269 | doi = 10.1002/elps.200800377 | s2cid = 6594113 }}</ref>
			==References==
			{{reflist}}å
			{{Chemotherapeutic agents}}
			{{Portal bar | Medicine}}
			{{Authority control}}
			]
			]
			]
			]
			]
			]
			]
			]